Rituximab-cdxx (Zimrixby)
Dilution requiredFull monograph review pending
U.S. label preparation
Zimrixby · Dilution required
- Preparation
- Dilute the 10 mg/mL vial to 1 to 4 mg/mL in 0.9% sodium chloride or 5% dextrose. Gently invert to mix.
- Administration and handling
- Use the applicable first or subsequent infusion rate schedule in the label. Premedication and infusion-reaction monitoring are required.
Product and source details
Dr. Reddy's Laboratories SA · BLA761376
FDA labeling action 2026-07-31. Checked 2026-11-13.
Source for this summary: U.S. prescribing information. Use the full label for dose selection, contraindications, preparation tables and monitoring.
Product identifiers and clinical review status
U.S. label preparation available. Full monograph review pending.
Exact formulation, concentration, container, manufacturer, regulatory identifiers, and a reproducible label snapshot have not all been reconciled.
What remains to be completed
- Obtain independent corroboration of the label preparation where available.
- Complete indication- and age-specific dosing, incompatibility, monitoring and stability review.
- Assess any proposed compounding BUD for the exact formulation, concentration, container and conditions.